WO2007061868A3 - Treatment of stereotypic, self-injurious and compulsive behaviors using specific serotonin reuptake inhibitors and antagonists of nmda receptors - Google Patents

Treatment of stereotypic, self-injurious and compulsive behaviors using specific serotonin reuptake inhibitors and antagonists of nmda receptors Download PDF

Info

Publication number
WO2007061868A3
WO2007061868A3 PCT/US2006/044720 US2006044720W WO2007061868A3 WO 2007061868 A3 WO2007061868 A3 WO 2007061868A3 US 2006044720 W US2006044720 W US 2006044720W WO 2007061868 A3 WO2007061868 A3 WO 2007061868A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
stereotypic
serotonin reuptake
injurious
antagonists
Prior art date
Application number
PCT/US2006/044720
Other languages
French (fr)
Other versions
WO2007061868A2 (en
Inventor
Louis Shuster
Nicholas H Dodman
Original Assignee
Tufts College
Louis Shuster
Nicholas H Dodman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tufts College, Louis Shuster, Nicholas H Dodman filed Critical Tufts College
Publication of WO2007061868A2 publication Critical patent/WO2007061868A2/en
Publication of WO2007061868A3 publication Critical patent/WO2007061868A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A combination of a specific serotonin reuptake inhibitor (SSRI) and an NMDA receptor antagonist can be used in methods of treatment, for reducing the frequency of stereotypic behaviors in animals and for reducing the frequency of analogous compulsive behaviors in humans, for example, those that have been said to be a manifestation of, or related to, obsessive-compulsive disorder.
PCT/US2006/044720 2005-11-17 2006-11-17 Treatment of stereotypic, self-injurious and compulsive behaviors using specific serotonin reuptake inhibitors and antagonists of nmda receptors WO2007061868A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US73771005P 2005-11-17 2005-11-17
US60/737,710 2005-11-17
US74280505P 2005-12-05 2005-12-05
US60/742,805 2005-12-05

Publications (2)

Publication Number Publication Date
WO2007061868A2 WO2007061868A2 (en) 2007-05-31
WO2007061868A3 true WO2007061868A3 (en) 2008-05-02

Family

ID=37992163

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/044720 WO2007061868A2 (en) 2005-11-17 2006-11-17 Treatment of stereotypic, self-injurious and compulsive behaviors using specific serotonin reuptake inhibitors and antagonists of nmda receptors

Country Status (1)

Country Link
WO (1) WO2007061868A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201701853YA (en) 2014-09-15 2017-04-27 Rugen Holdings Cayman Ltd Pyrrolopyrimidine derivatives as nr2b nmda receptor antagonists
WO2016126869A1 (en) 2015-02-04 2016-08-11 Rugen Holdings (Cayman) Limited 3,3-difluoro-piperidine derivatives as nr2b nmda receptor antagonists
ES2784398T3 (en) 2015-06-01 2020-09-24 Rugen Holdings Cayman Ltd 3,3-Difluoropiperidine carbamate heterocyclic compounds as NMDA NR2B receptor antagonists
WO2018098128A1 (en) * 2016-11-22 2018-05-31 Rugen Holdings (Cayman) Limited Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders
EP3968977A4 (en) * 2019-05-15 2023-01-11 The Trustees of Columbia University in the City of New York Compositions and methods against stress-induced affective disorders and their associated symptoms

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000002551A2 (en) * 1998-07-13 2000-01-20 Nps Pharmaceuticals, Inc. Methods and compounds for treating depression
US20020035105A1 (en) * 1997-05-07 2002-03-21 Caruso Frank S. Composition and method combining an antidepressant with an NMDA receptor antagonist, for treating neuropathic pain
WO2005000216A2 (en) * 2003-05-27 2005-01-06 Forest Laboratories, Inc. Combination of an nmda receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders
WO2006034187A2 (en) * 2004-09-20 2006-03-30 Mount Sinai School Of Medicine Use of memantine (namenda) to treat autism, compulsivity, and impulsivity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020035105A1 (en) * 1997-05-07 2002-03-21 Caruso Frank S. Composition and method combining an antidepressant with an NMDA receptor antagonist, for treating neuropathic pain
WO2000002551A2 (en) * 1998-07-13 2000-01-20 Nps Pharmaceuticals, Inc. Methods and compounds for treating depression
WO2005000216A2 (en) * 2003-05-27 2005-01-06 Forest Laboratories, Inc. Combination of an nmda receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders
WO2006034187A2 (en) * 2004-09-20 2006-03-30 Mount Sinai School Of Medicine Use of memantine (namenda) to treat autism, compulsivity, and impulsivity

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CORIC ET AL: "Riluzole Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder: An Open-Label Trial", BIOLOGICAL PSYCHIATRY, ELSEVIER SCIENCE, NEW YORK, NY, US, vol. 58, no. 5, 1 September 2005 (2005-09-01), pages 424 - 428, XP005015153, ISSN: 0006-3223 *
DOBLE A: "THE PHARMACOLOGY AND MECHANISM OF ACTION OF RILUZOLE", NEUROLOGY, LIPPINCOTT WILLIAMS & WILKINS, PHILADELPHIA, US, vol. 47, no. 6, 1996, pages S233 - S241, XP000910833, ISSN: 0028-3878 *
GRANT JON E ET AL: "Effectiveness of pharmacotherapy for pathological gambling: a chart review.", ANNALS OF CLINICAL PSYCHIATRY : OFFICIAL JOURNAL OF THE AMERICAN ACADEMY OF CLINICAL PSYCHIATRISTS SEP 2002, vol. 14, no. 3, September 2002 (2002-09-01), pages 155 - 161, XP002467929, ISSN: 1040-1237 *
MCDOUGLE C J ET AL: "Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder: A double-blind, placebo-controlled study in patients with and without tics", ARCHIVES OF GENERAL PSYCHIATRY 1994 UNITED STATES, vol. 51, no. 4, 1994, pages 302 - 308, XP008088333, ISSN: 0003-990X *
PASQUINI M ET AL: "Memantine augmentation for refractory obsessive-compulsive disorder", PROGRESS IN NEURO-PSYCHOPHARMACOLOGY AND BIOLOGICAL PSYCHIATRY 30 AUG 2006 UNITED STATES, vol. 30, no. 6, 30 August 2006 (2006-08-30), pages 1173 - 1175, XP002467930, ISSN: 0278-5846 *
ROGOZ Z ET AL: "Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats", NEUROPHARMACOLOGY, PERGAMON PRESS, OXFORD, GB, vol. 42, no. 8, June 2002 (2002-06-01), pages 1024 - 1030, XP002288820, ISSN: 0028-3908 *

Also Published As

Publication number Publication date
WO2007061868A2 (en) 2007-05-31

Similar Documents

Publication Publication Date Title
WO2005000216A8 (en) Combination of an nmda receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders
WO2012003418A3 (en) Functionally selective ligands of dopamine d2 receptors
WO2010037054A3 (en) Heteroaryl antagonists of prostaglandin d2 receptors
TW200730168A (en) Combination of an H3 antagonist/inverse agonist and an appetite suppressant
WO2010003120A3 (en) Antagonists of prostaglandin d2 receptors
ZA200705879B (en) CGRP antagonists, method for production thereof, and their use as medicaments
WO2007089318A3 (en) Compositions and methods for reducing food cravings
EP2137947A4 (en) Methods, systems, and computer program products for jumping calls between different modes of the same device
BRPI0517091A (en) and method for treating a disease or condition by altering an opioid receptor-mediated response
WO2005079756A3 (en) Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions
GB2453058A (en) Kinase antagonists
ZA200502247B (en) Selected CGRP antagonists, method for production and use thereof as medicament.
WO2007120689A3 (en) Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
IL186090A0 (en) Cgrp antagonists, method for the production thereof, and their use as medicaments
EP2209476A4 (en) Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of toll-like receptor-4-associated disorders
WO2008087491A8 (en) Method for treating or preventing symptoms of hormonal variations
WO2010057118A3 (en) Heterocyclic antagonists of prostaglandin d2 receptors
WO2007095161A3 (en) Methods and compositions for treating disorders associated with increased bone turnover and osteopenia
WO2009117669A3 (en) Treatment with opioid antagonists and mtor inhibitors
WO2007061868A3 (en) Treatment of stereotypic, self-injurious and compulsive behaviors using specific serotonin reuptake inhibitors and antagonists of nmda receptors
WO2007059300A3 (en) Anti-alk antagonist and agonist antibodies and uses thereof
WO2014049536A3 (en) Drug targets for cystic fibrosis and other conditions
HK1155943A1 (en) Combination of a nicotinic receptor partial agonist and of an acetylcholinesterase inhibitor, pharmaceutical composition containing same and use thereof in the treatment of cognitive disorders
CL2007002611A1 (en) COMPOUNDS DERIVED FROM ETER DIARILICO, ANTAGONISTS OF THE OPIOID RECEPTORS MU, KAPPA AND DELTA; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF OBESITY.
WO2008079727A3 (en) Compositions comprising an pan-alpha-2 receptor agonist and an anticonvulsant for treating chronic pain

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06837938

Country of ref document: EP

Kind code of ref document: A2